WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark CSL SEQIRUS was filed as Word mark on 08/10/2022 at the World Intellectual Property Organization.
| Trademark form | Word mark |
| File reference | 1701927 |
| Countries | 
|
| Base trademark |
No. UK00003818406,
August 10, 2022
|
| Application date | August 10, 2022 |
| Expiration date | August 10, 2032 |
Trademark owner
Point, 29 Market Street
Maidenhead, Berkshire SL6 8AA
GB
Maidenhead, Berkshire SL6 8AA
GB
Trademark representatives
100 New Bridge Street
London EC4V 6JA
GB
goods and services
01
Chemical and biological reagents in this class; cell
cultures and media in this class; laboratory and scientific
test kits in this class; chemical preparations for
scientific and/or industrial purposes; diagnostic and
testing agents; chemical and biological reagents for
non-medical purposes; chemical and biological reagents for
industrial use for anti-body screening, blood grouping, and
for the typing and detection of specific blood cells,
determining the presence of antigens on blood cells, and the
detection of relevant complement compounds and
immunoglobulin subtypes; chemical test kits for the
detection of specific blood cells, determining the presence
of antigens on blood cells, and the detection of relevant
complement compounds and immunoglobulin subtypes for
laboratory or research use; chemical preparations for
industrial use for anti-body screening, blood grouping, and
the typing and detection of specific blood cells
05
Pharmaceutical preparations and substances in this class;
vaccines; blood products; products derived from blood and
products derived from recombinant DNA technology; serums;
antibodies; medical and veterinary test kits; influenza
vaccines; adjuvants and antigens; pharmaceutical
preparations and substances for the treatment and/or
prevention of blood or bleeding disorders; blood products,
namely, blood plasma, reagent blood cells; products derived
from blood and products derived from recombinant DNA
technology, namely, immunoglobulins, human albumin, blood
clotting factors, plasma volume expanders, blood proteins
for therapeutic use; serums, namely, anti-venoms; medicated
serums for the treatment of blood or bleeding disorders;
test kits, namely, invitro diagnostic reagent test kits for
use in detecting cell mediated immune response;
pharmaceutical preparations and substances, namely, RhD
reagents for the detection of specific antigens or in blood
typing; pharmaceutical preparations, namely, reagent red
blood cells used to detect antibodies or IgG subtypes;
pharmaceutical preparations, namely, monoclonal and
polyclonal antibodies; pharmaceutical preparations, namely,
reagents for medical/clinical use for the typing and
detection of specific blood cells, and the detection of
relevant compliment components and immunoglobulin subtypes
41
Education services including medical education services;
health education; consultancy services relating to
education; provision of education services via an online
forum; provision of training and education courses;
publication of educational materials; dissemination of
educational material; weblog (blog) services; electronic
publication of information on a wide range of topics,
including online and over a global computer network
42
Scientific and technological services; research and
development services relating to scientific, medical,
pharmaceutical and blood products; industrial analysis;
clinical trials; conducting clinical trials; provision of
testing facilities; rental of research facilities;
laboratory analysis and research; management of scientific
research projects; preparation of technical studies,
technical reports, scientific reports; management of
scientific research projects, preparation of scientific and
medical research projects, preparation of statistics or
reports relating to scientific and medical research;
provision of research services and facilities, provision of
research results, information and outcomes; provision of
information relating to the aforementioned services;
advisory and consultancy services relating to the
aforementioned services; dissemination of information
relating to the aforementioned services over a global
computer network; medical laboratory services, namely,
scientific testing and screening services, namely, testing
of human blood plasma for safety and quality; medical
laboratory services regarding human blood plasma
44
Medical services; medical information services; health care
services; health care information services; patient support
services; providing medical information concerning blood
products; providing medical information concerning vaccines,
anti-venoms and immunohaematology products, namely,
diagnostic reagents; patient support services, namely,
providing patient medical information where patients can
enquire about medical issues and procedures from other
patients and can relay information about their medical
experiences for support and community via an internet-based
database
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| August 8, 2023 | 2023/32 Gaz | CW | Rejection |
| July 21, 2023 | 2023/30 Gaz | SX | Rejection |
| July 20, 2023 | 2023/29 Gaz | KZ | Rejection |
| June 15, 2023 | 2023/24 Gaz | SM | Rejection |
| June 12, 2023 | 2023/24 Gaz | RS | Rejection |
| June 8, 2023 | 2023/23 Gaz | RO | Rejection |
| April 21, 2023 | 2023/16 Gaz | AU | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| April 5, 2023 | 2023/14 Gaz | DZ | Rejection |
| March 28, 2023 | 2023/13 Gaz | MC | Rejection |
| March 9, 2023 | 2023/10 Gaz | RU | Rejection |
| February 16, 2023 | 2023/9 Gaz | IL | Rejection |
| January 31, 2023 | 2023/6 Gaz | NZ | Rejection |
| January 28, 2023 | 2023/9 Gaz | GB | RAW: Partial Ceasing Effect |
| January 10, 2023 | 2023/2 Gaz | AU | Rejection |
| January 9, 2023 | 2023/2 Gaz | IN | Rejection |
| August 10, 2022 | 2022/48 Gaz | GB | Registration |
ID: 141701927